Psilocybin research has exploded over the past decade, opening new conversations around depression, trauma, neuroplasticity and mental health. But beneath all the excitement sits a quieter issue that researchers are increasingly being forced to confront.
Most psychedelic science has been built around a surprisingly narrow model of biology.
The majority of foundational studies (both animal research and clinical work) have historically focused on adult male subjects. That includes much of what we know about serotonin receptors and the brain systems psilocybin interacts with.
A new study published in Neuropharmacology suggests that gap may matter more than many realised.
According to new animal research, estrogen levels appear to directly influence how the brain responds to psilocybin. That doesn’t mean psilocybin works for some people and not others. But it may mean that sensitivity to the compound fluctuates more dynamically than psychedelic science has traditionally assumed.
The Brain Doesn’t Respond to Psilocybin Identically
The study, led by A.L. Zylko and M.S. McMurray at Miami University, set out with a fairly straightforward question.
How do rats at different life stages respond to psilocybin?
Researchers compared adolescent and adult rats using a well-established behavioural measure commonly used in psychedelic research. The behaviour is known as the head-twitch response: a rapid full-body shaking movement triggered when serotonin receptors of the same type targeted by psilocin become activated.
It’s not a perfect stand-in for human psychedelic experience, but it’s widely used as a biological proxy for serotonergic activity in rodents.
The differences were immediate. Adult rats reacted strongly.
Within five minutes of receiving psilocybin, researchers observed a robust increase in the shaking behaviour associated with receptor activation.
The adolescent rats told a different story. Both early and late adolescent groups showed almost no response.
That finding alone makes the study interesting. It suggests the adolescent brain may process psilocybin through a different neurological framework, potentially tied to the way serotonin systems develop during periods of active brain growth and pruning.
Importantly, researchers are careful not to overstate what this means. A muted shaking response does inte mean psilocybin had no effect. Rather, adolescent brains may simply express those effects through different behavioural or neurological pathways that weren’t captured by this particular measurement.
Still, functional sensitivity — as measured here — appeared noticeably reduced.
The Unexpected Discovery
While analysing the adult animals, the research team noticed something they hadn’t originally designed the study to investigate.
Adult female rats were reacting more strongly than adult males receiving the same dose and the difference was large enough to trigger a second line of investigation. Researchers shifted their attention toward the estrous cycle (the rodent equivalent of the human menstrual cycle) to see whether hormones were shaping the response.
Over two weeks, they tracked hormonal changes and administered psilocybin during two distinct phases.
The first was diestrus, when estrogen levels are relatively low.
The second was proestrus, when estrogen peaks.
The results aligned directly with hormone levels.
During low-estrogen phases, the female rats displayed significantly more of the drug-induced shaking behaviour.
During peak estrogen phases, that response became noticeably dampened.
The pattern was surprisingly clear: more estrogen, less sensitivity to psilocybin. Less estrogen, more sensitivity.
Why Might Estrogen Matter?
The researchers’ working hypothesis centres on the serotonin 2A receptor.
This receptor is the primary gateway through which psilocin (the active metabolite of psilocybin) produces its effects. According to the proposed mechanism, estrogen may influence where these receptors sit and how they behave.
Hormonal shifts could cause serotonin 2A receptors to move inward from the cell surface, effectively making them harder for psilocin to access, while estrogen may also alter the signalling cascades that occur after receptor activation.
In simple terms: hormones may change not only whether psilocybin reaches its target efficiently, but also how the brain responds once it does. This fits with a broader understanding of how the body works.
The brain is not an isolated machine operating independently of everything else, it exists in constant conversation with the endocrine system. Hormones influence far more than reproduction. Estrogen is already known to shape cognition, mood regulation, emotional processing and neuroplasticity.
This study suggests psychedelic sensitivity may belong on that list too.
What About Adolescence?
One of the more reassuring aspects of the research lies in what researchers inte find. After the adolescent rats matured into adulthood, the team revisited them for follow-up testing, and they assessed anxiety behaviour, cognitive flexibility and adult sensitivity to psilocybin.
The outcome was surprisingly consistent.
Rats exposed to psilocybin during adolescence performed essentially identically to those that had never received it and no lasting anxiety differences emerged. No impairment in adapting to changing rules— a marker often associated with cognitive flexibility and depression — was detected.
And adult sensitivity to psilocybin appeared unchanged.
At this dose, a single adolescent exposure left no measurable behavioural footprint.
That finding adds nuance to a conversation that can sometimes become overly simplified.
Of course, the researchers are not presenting this as evidence that adolescent psychedelic use is harmless. Different doses, repeated exposure, alternative testing methods and subtle structural brain changes were not assessed here.
Adolescent brains naturally possess unusually high plasticity, which may also conceal effects not captured by behavioural testing alone.
So while this is not a green light, it does complicate the assumption that any psychedelic exposure during development automatically produces catastrophic outcomes.
What This Could Mean for Psychedelic Therapy
The broader implications may be where this research becomes most relevant. If estrogen meaningfully influences psilocybin sensitivity, then a standardised psychedelic dose may not be creating the same experience across different bodies.
That matters.
Modern psychedelic therapy tends to revolve around three familiar pillars:
Set. Setting. Dose.
This research suggests biology deserves a place alongside them.
A person in a lower-estrogen phase may experience a stronger response than they would at another point in their cycle.
The same person, receiving the same dose, in the same room, with the same therapist, could potentially have a meaningfully different experience depending on hormonal state. That possibility may help explain some of the variability researchers currently attribute primarily to psychology, intention or preparation.
It also opens important questions for groups often underrepresented in psychedelic research.
What about post-menopausal women?
What about hormonal contraceptives, which flatten natural estrogen fluctuations?
What about anyone whose hormonal baseline differs from the male physiological model much of psychedelic science has historically relied upon?
These questions are increasingly difficult to ignore.
A More Personalised Future for Psychedelic Medicine
Psychedelic therapy is steadily moving toward precision. Early research focused on whether compounds like psilocybin worked at all, but now the conversation is becoming more sophisticated.
Who responds best?
Why?
And under what biological conditions?
This new study doesn’t provide final answers.
Animal models are not human therapy rooms, and translating rodent data into clinical practice requires caution, but the findings do point toward something valuable.
Psilocybin interacts with the whole body. And if hormones shape that dialogue, psychedelic medicine may eventually become far more personalised than the field once imagined.
For now, the message is less about certainty and more about refinement. Psilocybin research is growing up. And understanding how biology influences experience may be part of what helps the next generation of psychedelic therapy become smarter, safer and more effective.
